April 25, 2023 -Findings show that MolecuLight is an Objective and Equitable Diagnostic Technology Positioned to Help Level Racial Disparity in Wound Care Outcomes
TORONTO, ON – (April 25, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication
… Read More
April 19, 2023 -Successful completion of recent audit demonstrates MolecuLight’s commitment to data security
TORONTO, ON – (April 19, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced that it is in compliance with SOC 2® Type I, having successfully
… Read More
February 14, 2023 -Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection Management
TORONTO, ON – (February 14, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication
… Read More
December 6, 2022 -Article is a Follow-On to MolecuLight’s Receipt an Innovative Technology Contract from Vizient Last Year
PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is featured in Vizient’s newly released Tech Watch publication as a
… Read More
November 10, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Salt Lake City, UTAH – (November 10, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that
… Read More
October 13, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Las Vegas, NEVADA – (October 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that over
… Read More
September 29, 2022 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA (September 29, 2022) –MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with AllSpire Health
… Read More
September 13, 2022 -Wide-Spread Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and Sydney, AUSTRALIA – (September 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that its
… Read More
August 11, 2022 -New Financing to Meet Significant Growth in Global Demand for MolecuLight’s i:X® and DX™ Point-of-Care Imaging Devices for the Wound Care Industry
Toronto, CANADA – (August 11, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has
… Read More 
